Abbott to spin off Nutrition business into independent public company by end‑2027
+3 new sources since this summary was written
Abbott Laboratories announced it will separate its Nutrition unit into a stand‑alone, publicly traded company, targeting completion by the end of 2027. The new entity is expected to generate about $8.5 billion of annual sales and will be led by Daniel Salvadori as chief executive officer. Abbott said the split will be tax‑free for shareholders, will not affect its 2026‑2027 guidance, and will involve one‑time transaction costs.
Why it matters
The company expects the combined dividend to remain unchanged after the spin‑off. Abbott disclosed it will incur one‑time charges related to the transaction, which could modestly reduce near‑term earnings. The separation creates two distinct businesses, potentially altering growth and margin profiles for investors.
Key facts
- 1Separation is expected to be completed by the end of 2027. stocktitan.net
- 2The new Nutrition company will have approximately $8.5 billion in annual sales. prnewswire.com
- 3Abbott will have sales of approximately $42 billion after the transaction. prnewswire.com
- 4Daniel Salvadori will become chief executive officer of the new Nutrition company. prnewswire.com
- 5The split will be executed as a tax‑free distribution to Abbott shareholders. stocktitan.net
- 6Abbott expects to incur one‑time charges related to the transaction, amount to be quantified later. stocktitan.net
Open questions
- Pre‑market share price decline reported as 1.55% versus 3.61%.
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.